このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発グレードII~III髄膜腫患者の治療におけるイピリムマブ併用または非併用のニボルマブおよびマルチフラクション定位放射線手術

2026年11月11日 更新者:National Cancer Institute (NCI)

再発性高悪性度放射線再発髄膜腫に対するマルチフラクション定位放射線手術と組み合わせたニボルマブプラスまたはマイナスイピリムマブの第I / II相研究

This phase I/II trial studies the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating patients with grade II-III meningioma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving nivolumab and multi-fraction stereotactic radiosurgery with or without ipilimumab may work better in treating patients with grade II-III meningioma.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVES:

I. To evaluate the maximum tolerated combination and safety profile of multi-fraction radiosurgery with concurrent nivolumab plus or minus ipilimumab for recurrent radiation-relapsed high-grade meningioma. (Phase I) II. To evaluate the objective response rate (ORR), either complete response or partial response as assessed on magnetic resonance imaging (MRI) per the modified Macdonald Criteria, of multi-fraction radiosurgery with concurrent nivolumab plus or minus ipilimumab for recurrent radiation-relapsed high-grade meningioma. (Phase II)

SECONDARY OBJECTIVE:

I. To evaluate duration of overall response, progression-free survival (PFS) and overall survival (OS) of recurrent radiation-relapsed high-grade meningioma patients treated with the combination of multi-fraction radiosurgery and nivolumab plus or minus ipilimumab.

CORRELATIVE OBJECTIVES:

I. To analyze the immunophenotype changes of peripheral T-cells during the treatment with multi-fraction radiosurgery in combination with nivolumab plus or minus ipilimumab.

II. To perform molecular profiling assays on pretreatment/baseline archival tumor, including, but not limited to, whole exome sequencing (WES) and messenger ribonucleic acid (RNA) sequencing (RNAseq), in order to IIa. Identify potential predictive and prognostic biomarkers (such as neoantigen signature or mutation burden) beyond any genomic alteration by which treatment may be assigned.

IIb. Identify resistance mechanisms using genomic deoxyribonucleic acid (DNA)- and RNA-based assessment platforms.

III. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome.

IV. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the National Cancer Institute Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank).

OUTLINE: This is a phase I, dose-escalation study of nivolumab followed by a phase II study. Patients are randomized to 1 of 2 cohorts.

COHORT A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.

COHORT B: Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.

Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo echocardiography (ECHO) as clinically indicated.

After completion of study treatment, patients are followed up for 100 days.

研究の種類

介入

入学 (推定)

38

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85054
        • Mayo Clinic Hospital in Arizona
    • California
      • Duarte、California、アメリカ、91010
        • City of Hope Comprehensive Cancer Center
      • La Jolla、California、アメリカ、92093
        • UC San Diego Moores Cancer Center
      • Los Angeles、California、アメリカ、90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles、California、アメリカ、90033
        • Los Angeles General Medical Center
      • Orange、California、アメリカ、92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • UCHealth University of Colorado Hospital
    • Florida
      • Aventura、Florida、アメリカ、33180
        • UM Sylvester Comprehensive Cancer Center at Aventura
      • Coral Gables、Florida、アメリカ、33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach、Florida、アメリカ、33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Jacksonville、Florida、アメリカ、32224-9980
        • Mayo Clinic in Florida
      • Miami、Florida、アメリカ、33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami、Florida、アメリカ、33176
        • UM Sylvester Comprehensive Cancer Center at Kendall
      • Plantation、Florida、アメリカ、33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • University of Kansas Cancer Center
      • Westwood、Kansas、アメリカ、66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • Mayo Clinic in Rochester
    • Missouri
      • Creve Coeur、Missouri、アメリカ、63141
        • Siteman Cancer Center at West County Hospital
      • St Louis、Missouri、アメリカ、63110
        • Washington University School of Medicine
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • University of Nebraska Medical Center
    • New York
      • New York、New York、アメリカ、10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York、New York、アメリカ、10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27599
        • UNC Lineberger Comprehensive Cancer Center
      • Durham、North Carolina、アメリカ、27710
        • Duke University Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Thomas Jefferson University Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Hillman Cancer Center
    • Texas
      • Dallas、Texas、アメリカ、75390
        • UT Southwestern/Simmons Cancer Center-Dallas
    • Utah
      • Salt Lake City、Utah、アメリカ、84112
        • Huntsman Cancer Institute/University of Utah

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have histologically confirmed World Health Organization (WHO) grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease

  • Patients must have measurable disease, defined as at least 1 lesion that can be accurately measured in at least one dimension as >= 1 cm on brain magnetic resonance imaging (MRI) but with the maximum dimension =< 5 cm OR gross tumor volume < 20 cm^3. All the relapsed disease would need to be eligible to be treated with reirradiation

  • Patients must have at least one prior surgery with available archival formalin-fixed paraffin-embedded (FFPE) tumor blocks of the initial or recurrent meningioma. If there are multiple tumor blocks from multiple surgeries, the most recent tumor block (and ideally of the relapsed tumor after initial radiation therapy) should be submitted. If a tumor block is not available, an alternative of 20-30 unstained slides may be submitted instead. Annotation regarding whether the tumor block is before or after initial radiation therapy should be provided

  • Prior initial radiation therapy may include external beam radiation or radiosurgery, or combination of both. However, the total dose of prior radiation exposure to the site of recurrent tumor (for consideration of re-irradiation) cannot be more than 70 Gy. The duration since the previous radiation exposure to the site of reirradiation need to be at least 6 months

  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Leukocytes >= 3,000/mcL

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN

  • Serum creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 for patients with creatinine levels above 1.5 x institutional normal

  • The effects of nivolumab and/or ipilimumab on the developing human fetus are unknown. For this reason and because radiation therapy is known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception

    • Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
    • WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 100 days
    • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document or, if decision-making capacity is impaired, consent of a legally authorized representative (e.g., spouse, adult child, live-in caretaker).

Exclusion Criteria:

  • Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study

  • Patients who have had radiation therapy (to the site of reirradiation) within 6 months prior to entering the study

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); however, alopecia, sensory neuropathy =< grade 2, or other =< grade 2 not constituting a safety risk based on the investigator's judgment are acceptable

  • Patients who are receiving any other investigational agents

  • Patients who have previous treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab and/or ipilimumab

  • History of severe hypersensitivity reaction to any monoclonal antibody

  • Current use of immunosuppressive medication (EXCEPT for the following: Intranasal, inhaled, topical steroids, or local steroid injection [e.g. intra-articular injection]; systemic corticosteroids at doses =< 4 mg/day of dexamethasone or equivalent; steroids as premedication for hypersensitivity reactions [e.g. computed tomography (CT) scan premedication])

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. However, patients with human immunodeficiency virus (HIV) on stable therapy with minimal viral loads and patients with hepatitis B and hepatitis C who have received treatment with minimal viral loads will be eligible

  • Pregnant women are excluded from this study because radiation therapy is teratogenic and that the effects of nivolumab and/or ipilimumab on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab and/or ipilimumab, breastfeeding should be discontinued if the mother is treated with nivolumab and/or ipilimumab

  • Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

    • Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
  • Prior organ transplantation including allogeneic stem cell transplantation

  • Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study

  • Live vaccination within 4 weeks of the first dose of nivolumab and while on trial is prohibited except for administration of inactivated vaccines

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A (nivolumab, radiosurgery)

Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.

Undergo blood sample collection

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Undergo ECHO

他の名前:
  • 心エコー検査
  • EC

Given IV

他の名前:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • オプジーボ
  • CMAB819
  • ニボルマブ バイオシミラー CMAB819
  • MDX1106
  • BMS 936558
  • ABP206
  • ニボルマブ バイオシミラー ABP 206
  • BCD-263
  • ニボルマブ バイオシミラー BCD-263
  • BMS936558
  • 小野 4538
  • オノ4538

Undergo brain MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo multi-fraction stereotactic radiosurgery

他の名前:
  • 定位外部ビーム照射
  • 定位外照射療法
  • 定位放射線治療
  • 定位放射線手術
  • SRS
実験的:Cohort B (nivolumab, ipilimumab, radiosurgery)

Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5. Patients undergo brain MRI and blood sample collection throughout the study. Patients may also undergo ECHO as clinically indicated.

Undergo blood sample collection

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Given IV

他の名前:
  • 抗細胞傷害性 T リンパ球関連抗原 4 モノクローナル抗体
  • BMS-734016
  • イピリムマブ バイオシミラー CS1002
  • MDX-010
  • MDX-CTLA4
  • ヤーボイ
  • MDX010
  • BMS734016
  • BMS 734016

Undergo ECHO

他の名前:
  • 心エコー検査
  • EC

Given IV

他の名前:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • オプジーボ
  • CMAB819
  • ニボルマブ バイオシミラー CMAB819
  • MDX1106
  • BMS 936558
  • ABP206
  • ニボルマブ バイオシミラー ABP 206
  • BCD-263
  • ニボルマブ バイオシミラー BCD-263
  • BMS936558
  • 小野 4538
  • オノ4538

Undergo brain MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo multi-fraction stereotactic radiosurgery

他の名前:
  • 定位外部ビーム照射
  • 定位外照射療法
  • 定位放射線治療
  • 定位放射線手術
  • SRS

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
放射線手術とニボルマブとイピリムマブの併用の最大耐量 (フェーズ I)
時間枠:最大100日
最大100日
客観的奏効率(第II相)
時間枠:治療開始から少なくとも2年間の追跡期間を通じて
治療開始から少なくとも2年間の追跡期間を通じて
Incidence of adverse event profile (Phase I)
時間枠:Up to 100 days

Will be evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The number and percentage of subjects experiencing each type of adverse event will be tabulated by severity, and relationship to treatment. If appropriate, confidence intervals will be used to characterize the precision of the estimate. A complete listing of adverse events will also be tabulated, and will provide details including severity, relationship to treatment, onset, duration, and outcome. Laboratory data measured on a continuous scale will be characterized by summary statistics (mean and standard deviation).

Up to 100 days
Objective radiological response (Phase II)
時間枠:Up to 100 days

Will include either complete response or partial response as assessed on magnetic resonance imaging per the modified Macdonald Criteria. 80% confidence intervals will be calculated.

Up to 100 days

二次結果の測定

結果測定
メジャーの説明
時間枠
全体的な反応の持続期間
時間枠:治療開始から少なくとも2年間のフォローアップ期間を通じて
治療開始から少なくとも2年間のフォローアップ期間を通じて
Progression-free survival
時間枠:From the start of treatment to 6 months and 2 years

80% confidence intervals will be assessed using Kaplan-Meier product limit methods.

From the start of treatment to 6 months and 2 years
Overall survival
時間枠:From the start of treatment through at least two years of follow-up

80% confidence intervals will be assessed using Kaplan-Meier product limit methods.

From the start of treatment through at least two years of follow-up

その他の成果指標

結果測定
メジャーの説明
時間枠
Deoxyribonucleic acid sequencing
時間枠:Up to 100 days

Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample.

Up to 100 days
Ribonucleic acid expression
時間枠:Up to 100 days

Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample.

Up to 100 days
Neoantigen signature
時間枠:Up to 100 days

Will be explored by comparing the differences in theses biomarkers between responders versus non-responders using t-test or Mann-Whitney rank-sum test as appropriate. Permutation test will be used to determine whether the observed difference is larger than might be expected by chance, while the null distribution of test statistics will be generated using 10,000 permutation samples where the response status will be randomly re-shuffled. The observed test statistics will be compared to the null distributions. For each outcome, the permuted p-value will be the fraction of permuted samples that resulted in a small statistic than the original sample.

Up to 100 days
Changes of peripheral T-cells
時間枠:Baseline up to 100 days

Each T-cell subset will be quantified as a percentage of the overall T-cell population by normalizing to CD3+ cells. Linear mixed model for repeated measurement data will be used to assess the change over time as well as the differences between subgroups (e.g., responders vs. non-responders) for immunogenicity and other biomarkers (i.e., frequency of CD8+Ki67+PD1+ T-cells, etc.). Receiver operating characteristic (ROC) curves will also be used to assess the overall predictive ability and to explore the optimal cut-off points for baseline biomarkers to differentiate responders versus non-responders.

Baseline up to 100 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jiayi Huang、Yale University Cancer Center LAO

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年6月17日

一次修了 (推定)

2027年3月19日

研究の完了 (推定)

2027年3月19日

試験登録日

最初に提出

2018年7月27日

QC基準を満たした最初の提出物

2018年7月27日

最初の投稿 (実際)

2018年7月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2018-01560
  • UM1CA186689 (米国 NIH グラント/契約)
  • UM1CA186704 (米国 NIH グラント/契約)
  • NCI-2018-01560 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • 201901009
  • 10186 (その他の識別子:CTEP)
  • 10186 (その他の識別子:Yale University Cancer Center LAO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。